Compare Salesforce Inc (CRM) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Moderna, Inc. — how do they compare? Salesforce Inc trades at $196.35 (market cap $158.33B), while Moderna, Inc. trades at $63.81 (market cap $25.42B). The key difference: Salesforce Inc is far larger — about 6.2× Moderna, Inc.'s market cap, and Salesforce Inc pays a 0.91% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| CRM | MRNA | |
|---|---|---|
Market Cap | $158.33B | $25.42B |
Sector | Technology | Health |
52-Week High | $266.23 | $81.80 |
52-Week Low | $150.12 | $22.36 |
Enterprise Value | $188.38B | $21.57B |
Dividend Yield | 0.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $197.47, down slightly by 0.02% on the day, with a bullish technical signal driven by moving averages. The stock has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $3.88 surpassing the $3.13 estimate. Revenue grew to $37.90B in 2025, and net income margin expanded to 16.35%. Analyst consensus is strongly bullish with a $231.91 price target, though recent news highlights sector-wide software stock volatility amid AI-driven market shifts.
The outlook remains positive given strong fundamentals and AI monetization progress, but risks include competitive pressures and macroeconomic sensitivity. The stock offers growth potential at a reasonable valuation (P/E 22.88), supported by robust cash flow and institutional buy-in, though investors should monitor execution on AI initiatives and broader tech sector sentiment.
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
